Biotech ETF Screams Higher on Increased M&A and Positive Earnings

ishares_logoIt was another solid week of gains for the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) as investors took their cue from bullish earnings reports out of Biogen (NASDAQ:BIIB) and Amgen (NASDAQ:AMGN), along with continued takeover rumors floating all around the biotech space.

Consolidation is certainly a theme that can drive further bullish momentum. The Medivation (NASDAQ:MDVN) auction process (as you can call it) has grabbed headlines for weeks, and just Friday we heard Sanofi (NYSE:SNY), Pfizer (NYSE:PFE), Gilead (NASDAQ:GILD), & Celgene (NASDAQ:CELG) have all expressed interested in bidding for MDVN. With the company acknowledging it would like to get a deal done, analysts feel a mid-August timeline could bring clarity to the situation.

This upcoming week will likely produce more rumors of deals not to mention earnings results from the likes of Regeneron Pharmaceuticals (NASDAQ:REGN) and BioMarin Pharmaceuticals (NASDAQ:BMRN).

Looking at the iShares Nasdaq Biotechnology ETF from a technical standpoint, the ETF cleared its 50-day moving average this week and will not have as much overhead resistance as it had prior. The ETF’s price range has been quite volatile this year from highs of $338-$340 early in 2016 to lows of in early February, the ETF has slowly been coming off those February lows but are still down 14.45% year-to-date.

Here’s a look at the top 10 holdings for IBB:

IBB-holdings-2016-07-31

And here’s what the ETF’s year-to-date chart looks like:

IBB-2016-07-31

Expect the fireworks to continue in coming weeks, with more earnings reports, M&A activity, and analyst calls sure to impact the always-volatile biotech space. Finally, just in case you missed it, be sure check out our recent post, A Biotech Investor’s Worst Nightmare Just Came True.

You are viewing an abbreviated republication of ETF Daily News content. You can find full ETF Daily News articles on (www.etfdailynews.com)

Powered by WPeMatico